Sentinel lymph node detection in thyroid carcinoma using [68Ga]Ga-tilmanocept PET/CT: A proof of concept study

niveristy Medical Center Utrecht0 个研究点目标入组 10 人开始时间: 2021年10月16日最近更新: 2021年12月6日

适应症

试验速览

暂无简介。

•All of the following criteria:
•The patient has provided written informed consent authorization before participating in the study
•Cytologic diagnosis of differentiated thyroid carcinoma (Bethesda 6) and will undergo a hemi- or total thyroidectomy, or cytologic diagnosis of medullary thyroid carcinoma(Bethesda 6)
•The patient is =18 years of age at time of consent
•The patient has an ECOG status of Grade 0 – 2
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 5
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 5

•Any of the following criteria:
•The patient is incapacitated
•The patient is pregnant or lactating
•The patient has a history of neck dissection, gross injury or radiotherapy to the neck that would preclude reasonable surgical dissection for this trial
•The patient will undergo minimally invasive thyroid surgery (via the axilla or trans-oral approach)
•The patient is actively receiving systemic cytotoxic chemotherapy.
•The patient is on immunosuppressive, anti-monocyte, or immunomodulatory therapy
•The patient has a preoperatively histologically proven multifocal tumor

发起方

niveristy Medical Center Utrecht